US Patent No: 4,599,230

Number of patents in Portfolio can not be more than 2000

Synthetic hepatitis B virus vaccine including both T cell and B cell determinants

3 Status Updates

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Chemically synthesized polypeptides include amino acid residue sequences that substantially correspond to the amino acid residue sequences of T cell and B cell determinant portions of a natural, pathogen-related protein, in particular, a hepatitis B virus surface antigen (HBsAg). When administered to a host alone, as polymers or as carrier-bound conjugates, the polypeptides induce the proliferation of thymus-derived cells in hosts primed against hepatitis B virus.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
THE SCRIPPS RESEARCH INSTITUTELA JOLLA, CA531

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Chisari, Frank V Del Mar, CA 2 218
Milich, David R San Diego, CA 17 418

Cited Art Landscape

Patent Info (Count) # Cites Year
 
The Regents of the University of California (2)
* 4,415,491 Synthetic vaccine peptide epitomes of hepatitis B surface antigen 35 1980
* 4,483,793 Dimeric oligopeptides as heptenic epitopic sites for hepatitis 6 1982
 
Institut Pasteur (1)
* 4,428,941 Nucleotidic sequence coding the surface antigen of the hepatitis B virus, vector containing said nucleotidic sequence, process allowing the obtention thereof and antigen obtained thereby 57 1981
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (7)
* 2002/0044,948 Methods and compositions for co-stimulation of immunological responses to peptide antigens 45 2001
* 2004/0018,971 Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions 7 2002
* 2003/0216,342 Expression vectors for stimulating an immune response and methods of using the same 3 2003
* 2003/0185,816 Solubilised protein vaccines 0 2003
* 2005/0032,039 HIV-specific T-cell induction 2 2003
* 2010/0203,074 COMPOSITIONS AND METHODS FOR TREATING INTRACELLULAR DISEASES 0 2010
* 2011/0124,047 VMP-LIKE SEQUENCES OF PATHOGENIC BORRELIA SPECIES AND STRAINS 0 2010
 
Genimmune N.V. (1)
* 2004/0248,113 Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby 3 2004
 
GFF GESELLSCHAFT ZUR FORDERUNG DER INDUSTRIEORIENTIERTEN FORSCHUNG (1)
* 6,596,278 Immunological response potentiation process 3 1995
 
Epimunne Inc. (1)
8,741,576 Heteroclitic analogs and related methods 0 2002
 
CHIRON CORPORATION (1)
* 4,722,840 Hybrid particle immunogens 111 1985
 
THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (1)
* 5,827,654 Basal body rod protein genes of campylobacter 1 1995
 
POWDERJECT VACCINES, INC. (1)
6,881,723 Nucleic acid constructs 0 1999
 
Medeva Holdings, B.V. (7)
* 6,020,167 Composition used as a therapeutic agent against chronic viral hepatic diseases 13 1994
* 6,022,543 Hepatitis B surface antigen vaccine 7 1994
6,589,530 Hepatitis B surface antigen vaccine 0 1995
* 6,117,653 Hepatitis B surface antigen vaccine 7 1995
* 6,110,706 Hepatitis B surface antigen vaccine 3 1995
* 6,100,065 Hepatitis B surface antigen vaccine 1 1995
* 6,072,049 Hepatitis B surface antigen vaccine 7 1995
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (15)
* 5,807,552 Compositions for conferring immunogenicity to a substance and uses thereof 14 1995
6,656,471 HIV-specific T-cell induction 9 1999
7,306,804 HIV-specific T-cell induction 0 2003
7,847,084 species and strains 6 2003
* 2006/0240,035 Vmp-like sequences of pathogenic borrelia species and strains 3 2003
7,316,907 14-3-3 zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer types 10 2004
7,627,938 Tapered hollow metallic microneedle array assembly and method of making and using the same 23 2004
* 2006/0084,942 Tapered hollow metallic microneedle array assembly and method of making and using the same 30 2004
7,803,363 bacteria 1 2007
* 2007/0248,622 ATTENUATED FRANCISELLA BACTERIA 0 2007
7,709,205 14-3-3 Zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer type 0 2007
8,076,470 species and strains 6 2010
8,283,458 species and strains 5 2011
8,722,871 VMP-like sequences of pathogenic borrelia species and strains 0 2012
9,115,193 species and strains 0 2014
 
EPIMMUNE INC. (11)
* 6,419,931 Compositions and methods for eliciting CTL immunity 25 1994
6,322,789 HLA-restricted hepatitis B virus CTL epitopes 7 1995
9,266,930 using peptide and nucleic acid compositions 0 1999
7,572,882 Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions 1 2000
7,462,354 Method and system for optimizing minigenes and peptides encoded thereby 1 2001
* 2003/0143,672 Heteroclitic analogs and related methods 5 2002
7,611,713 Inducing cellular immune responses to hepatitis B virus using peptide compositions 1 2003
* 2005/0063,983 Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions 1 2003
* 2007/0054,262 Methods of identifying optimal variants of peptide epitopes 5 2004
* 2009/0214,632 Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions 1 2008
* 2010/0049,491 Method and System for Optimizing Minigenes and Peptides Encoded Thereby 0 2008
 
GREEN CROSS CORPORATION (1)
* 4,694,074 Process for the purification of HBsAg 4 1985
 
Akshaya Bio Inc. (6)
8,029,803 Chimeric antigens for eliciting an immune response 1 2003
* 2004/0001,853 Chimeric antigens for eliciting an immune response 21 2003
8,025,873 Chimeric antigens for eliciting an immune response 2 2004
8,007,805 Chimeric antigens for breaking host tolerance to foreign antigens 2 2004
* 2011/0223,185 CHIMERIC HEPATITIS C VIRUS ANTIGENS FOR ELICITING AN IMMUNE RESPONSE 1 2011
8,465,745 Chimeric antigens for eliciting an immune response 0 2011
 
The Scripps Research Institute (11)
* 5,939,524 Platelet GPIII P1.sup.A1 and P1.sup.A2 epitopes, their preparation and use 11 1991
* 5,709,995 Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses 24 1994
* 5,780,036 Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus 16 1995
* 5,932,224 Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus 8 1995
6,607,727 Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus 5 1996
7,220,420 Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses 7 1997
* 2002/0115,061 PEPTIDES FOR INDUCING CYTOTOXIC T LYMPHOCYTE RESPONSES TO HEPATITIS C VIRIS 0 1997
7,763,589 Compositions and methods for treating intracellular diseases 0 1999
6,919,203 Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus 0 2001
* 2003/0171,538 Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus 3 2003
7,368,118 Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus 1 2005
 
INSTITUTE OF IMMUNOLOGY CO., LTD. (1)
* 5,019,386 Hepatitis B vaccine 18 1988
 
PHARMEXA INC. (7)
6,689,363 Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions 24 1999
* 2002/0160,960 HLA binding peptides and their uses 3 2002
* 2003/0099,634 Compositions and methods for eliciting CTL immunity 7 2002
* 2006/0093,617 Peptides for inducing a CTL and/or HTL response to hepatitis C virus 11 2005
* 2011/0097,352 Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions 0 2007
* 2009/0304,746 Inducing cellar immune responses to hepatitis C virus using peptide and nucleic acid compositions 9 2007
* 2010/0099,613 PEPTIDES FOR INDUCING A CTL AND/OR HTL RESPONSE TO HEPATITIS C VIRUS 5 2009
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (1)
* 5,019,384 Immunonodulating compositions and their use 29 1989
 
AVENTIS PASTEUR LIMITED (5)
6,764,682 Adjuvant compositions containing more than one adjuvant 2 1994
6,361,779 Transferrin receptor genes 0 1996
6,358,727 Haemophilus transferrin receptor genes 0 1996
6,290,971 Adjuvant compositions comprising a mineral salt and another immunostimulating compound 2 1997
6,262,016 Transferrin receptor genes 0 1997
 
TECHOLDING SA (1)
* 2005/0002,953 SARS-coronavirus virus-like particles and methods of use 8 2004
 
ITERATIVE THERAPEUTICS, INC. (6)
8,163,289 Methods and compositions involving polymeric immunoglobulin fusion proteins 0 2008
* 2008/0292,704 Methods and Compositions Involving Polymeric Immunoglobulin Fusion Proteins 1 2008
7,897,729 Polymeric immunoglobulin fusion proteins that target low affinity FcγReceptors 3 2008
* 2009/0117,133 POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW AFFINITY FCyRECEPTORS 3 2008
8,986,698 Method of using fusion proteins 0 2011
9,127,063 Nucleic acids related to fusion proteins 0 2013
 
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (1)
* 2007/0059,299 S-adenosyl methionine decarboxylase inhibition for the treatment of a herpes simplex virus infection 0 2003
 
GGMJ TECHNOLOGIES, L.L.C. (1)
* 5,348,867 Expression of proteins on bacterial surface 67 1991
 
AKSHAYA BIO INC. (2)
* 2005/0031,628 Chimeric antigens for breaking host tolerance to foreign antigens 4 2004
* 2005/0013,828 Chimeric antigens for eliciting an immune response 16 2004
 
H. LUNDBECK A/S (6)
7,135,181 Method for down-regulation of amyloid 17 2001
* 2002/0187,157 Novel method for down-regulation of amyloid 12 2001
* 2003/0086,938 Novel methods for down-regulation of amyloid 30 2002
* 2009/0092,579 NOVEL METHOD FOR DOWN-REGULATION OF AMYLOID 1 2008
8,871,212 Amyloid-beta polypeptide vaccine 0 2008
* 2010/0047,262 NOVEL METHOD FOR DOWN-REGULATION OF AMYLOID 0 2008
 
BIOTECH SYNERGY, INC. (1)
* 2004/0121,946 Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions 12 2002
 
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (11)
* 2008/0181,949 Nanoemulsion Vaccines 4 2007
* 2008/0181,905 Nanoemulsion Vaccines 2 2007
7,923,001 Compositions and methods for diagnosing and treating urinary tract infections 0 2008
* 2009/0068,220 COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING URINARY TRACT INFECTIONS 0 2008
9,415,006 Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same 0 2009
8,877,208 Multivalent nanoemulsion vaccines 3 2009
* 2010/0028,433 IMMUNOGENIC COMPOSITIONS COMPRISING NANOEMULSION AND HEPATITIS B VIRUS IMMUNOGEN AND METHODS OF USING THE SAME 1 2009
* 2009/0291,095 NANOEMULSION ADJUVANTS 4 2009
8,668,911 vaccine compositions and methods of using the same 0 2010
8,133,496 Compositions and methods for diagnosing and treating urinary tract infections 0 2011
* 2011/0229,512 COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING URINARY TRACT INFECTIONS 0 2011
 
PRAXIS BIOLOGICS, INC. (1)
* 5,785,973 Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines 32 1995
 
Cel-Sci Corporation (2)
* 5,652,342 Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same 12 1994
* 6,096,315 Heterofunctional cellular immunological reagents, vaccines containing same and methods for the use of same 3 1995
 
Longhorn Vaccines and Diagnostics, LLC (10)
8,821,885 Immunogenic compositions and methods 0 2008
* 2009/0081,202 IMMUNOGENIC COMPOSITIONS AND METHODS 9 2008
8,652,782 Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids 0 2011
9,416,416 Biological specimen collection/transport compositions and methods 0 2011
8,293,467 Biological specimen collection and transport system and methods of use 8 2011
9,080,204 Compositions and methods for rapid, real-time detection of influenza a virus (H1N1) Swine 2009 0 2011
8,415,330 Biological specimen collection and transport system and method of use 1 2012
8,669,240 Biological specimen collection and transport system and method of use 1 2013
9,212,399 Biological specimen collection and transport system and method of use 0 2014
9,388,220 Immunogenic compositions and methods 0 2014
 
BEALE STREET 143 INVEST APS (2)
7,097,837 Synthetic vaccine agents 20 2002
* 2002/0119,162 Synthetic vaccine agents 0 2002
 
THE GENERAL HOSPITAL CORPORATION (3)
9,044,606 Methods and devices for activating brown adipose tissue using electrical energy 0 2010
8,476,227 Methods of activating a melanocortin-4 receptor pathway in obese subjects 0 2010
9,381,219 Brown adipocyte modification 0 2011
 
OSE PHARMA INTERNATIONAL SA (1)
7,252,829 HLA binding peptides and their uses 8 1998
 
CONNAUGHT LABORATORIES LIMITED (8)
* 5,922,562 Nucleic acids encoding transferrin receptors 1 1994
* 6,020,125 Basal body rod protein FlgF of campylobacter 1 1995
* 6,015,688 Transferrin receptor genes 2 1995
* 6,008,326 Transferrin receptor antibodies 0 1995
* 5,922,323 Transferrin receptor genes and immunogenic compositions derived therefrom 1 1995
* 5,922,841 Recombinantly produced transferrin receptor of haemophilus 3 1995
* 5,837,250 Adjuvant compositions 3 1995
7,118,749 Transferrin receptor genes 1 2002
 
New York Blood Center, Inc. (4)
* 4,847,080 Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers 29 1985
* 4,861,588 Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers 25 1986
* 5,204,096 Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers 25 1989
* 5,565,548 Pre-S gene coded peptide hepatitis B immunogens and synthetic lipid vesicle carriers 23 1993
 
VLP BIOTECH (6)
7,320,795 Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof 3 2003
7,144,712 Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof 4 2003
* 2005/0025,782 Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof 2 2003
* 2005/0025,781 Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof 1 2003
7,883,843 Hepatitis virus core proteins as vaccine platforms and methods of use thereof 0 2004
7,811,576 Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof 0 2008
 
BAYLOR RESEARCH INSTITUTE (7)
9,102,734 Fusion proteins comprising antibody and HPV E6 and E7 antigens 0 2010
8,961,991 Anti-CD40 targeted fusion proteins 0 2010
8,518,410 Fusion protein with HIV antigen 1 2010
* 2010/0322,929 ANTIGEN PRESENTING CELL TARGETED CANCER VACCINES 2 2010
* 2010/0297,114 ANTIGEN PRESENTING CELL TARGETED VACCINES 0 2010
* 2010/0239,575 ANTI-CD40 ANTIBODIES AND USES THEREOF 7 2010
9,416,186 Antigen presenting cell targeted anti-viral vaccines 0 2013
 
Vaccine Research Institute of San Diego (1)
* 2011/0206,724 HEPATITIS VIRUS CORE PROTEINS AS VACCINE PLATFORMS AND METHODS OF USE THEREOF 0 2010
 
VECTOR NEUROSCIENCES LLC (3)
8,017,385 Use of apotosis inhibiting compounds in degenerative neurological disorders 1 2005
* 2006/0210,538 Use of apotosis inhibiting compounds in degenerative neurological disorders 19 2005
8,071,563 Glutamic acid decarboxylase (GAD) chimera and methods of use 0 2009
 
Statens Serum Institut (4)
* 2004/0086,949 Method for preparing a ligand presenting assembly (LPA), an LPA and uses thereof 1 2003
8,105,614 Expanding the T cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails 0 2007
* 2008/0008,724 Expanding the T cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails 10 2007
9,074,001 Tuberculosis TB vaccine to prevent reactivation 0 2010
 
The Johns Hopkins University (2)
9,138,470 Multi-component L2 vaccine for prevention of human papilloma virus infection 0 2008
* 2011/0177,112 MULTI- COMPONENT L2 VACCINE FOR PREVENTION OF HUMAN PAPILLOMA VIRUS INFECTION 1 2008
 
The University of Chicago (3)
9,241,987 Methods and compositions related to immunogenic fibrils 0 2010
9,095,540 Methods and compositions involving protective staphylococcal antigens 0 2011
8,945,588 Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides 1 2012
 
United Biomedical, Inc. (1)
* 5,106,726 Synthetic peptides specific for the detection of antibodies to HCV 72 1990
 
UNIVERSITE LIBRE DE BRUXELLES (3)
* 7,947,450 Device, kit and method for pulsing biological samples with an agent and stabilising the sample so pulsed 2 2008
8,067,172 Device, kit and method for pulsing biological samples with an agent and stabilising the sample so pulsed 0 2010
8,206,916 Device, kit and method for pulsing biological samples with an agent and stabilising the sample so pulsed 0 2011
 
DEVELOPMENT CENTER FOR BIOTECHNOLOGY (2)
8,110,197 heat-labile enterotoxin 0 2007
8,088,394 heat-labile enterotoxin 0 2008
 
Symbicom Aktiebolag (1)
6,610,838 P13 antigens from Borrelia 4 1998
 
Pharnexa A/S (1)
* 2007/0041,945 NOVEL METHOD FOR DOWN-REGULATION OF AMYLOID 3 2006
* Cited By Examiner